Stoke Therapeutics, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +3.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.82 | $-0.93 | -13.4% | Miss | Q2 FY26 call |
| Q1 FY26 | $-0.80 | $-0.79 | +1.3% | Beat | |
| Q4 FY25 | $-0.75 | $-0.97 | -29.3% | Miss | |
| Q3 FY25 | $-0.54 | $-0.65 | -20.4% | Miss | |
| Q2 FY25 | $-0.57 | $-0.40 | +29.8% | Beat | |
| Q1 FY25 | not reported | $1.90 | not reported | not reported | |
| Q4 FY24 | not reported | $-0.18 | not reported | not reported | |
| Q3 FY24 | $-0.52 | $-0.47 | +9.6% | Beat | |
| Q2 FY24 | $-0.57 | $-0.46 | +19.3% | Beat | |
| Q1 FY24 | $-0.60 | $-0.57 | +5.0% | Beat | |
| Q4 FY23 | $-0.62 | $-0.60 | +3.2% | Beat | |
| Q3 FY23 | $-0.65 | $-0.55 | +15.4% | Beat |
Back to STOK overview · STOK holders · STOK KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.